A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer's disease mouse model

Tumor necrosis factor-alpha (TNF-alpha) is a pleiotropic, proinflammatory cytokine related to different neurodegenerative diseases, including Alzheimer's disease (AD). Although the linkage between increased TNF-alpha levels and AD is widely recognized, TNF-alpha-neutralizing therapies have failed to treat AD. Previous research has associated this with the antithetic functions of the two TNF receptors, TNF receptor 1, associated with inflammation and apoptosis, and TNF receptor 2 (TNFR2), associated with neuroprotection. In our study, we investigated the effects of specifically stimulating TNFR2 with a TNFR2 agonist (NewStar2) in a transgenic A beta-overexpressing mouse model of AD by administering NewStar2 in two different ways: centrally, via implantation of osmotic pumps, or systemically by intraperitoneal injections. We found that both centrally and systemically administered NewStar2 resulted in a drastic reduction in amyloid beta deposition and beta-secretase 1 expression levels. Moreover, activation of TNFR2 increased microglial and astrocytic activation and promoted the uptake and degradation of A beta. Finally, cognitive functions were also improved after NewStar2 treatment. Our results demonstrate that activation of TNFR2 mitigates A beta-induced cognitive deficits and neuropathology in an AD mouse model and indicates that TNFR2 stimulation might be a potential treatment for AD.

Automated summary

This study investigated the effects of stimulating TNFR2 with a TNFR2 agonist (NewStar2) in an AD mouse model. The results demonstrated that activation of TNFR2 reduced amyloid beta deposition and expression of beta-secretase 1, increased microglial and astrocytic activation, promoted the uptake and degradation of A beta, and improved cognitive functions. These findings suggest that TNFR2 stimulation might be a potential treatment for AD.